Getinge AB B

Getinge is engaged in three business areas: Medical Systems, Extended Care and Infection Control. Medical System's product range includes surgical tables, surgical lamps, telemedicine, perfusion products, instruments for bypass operations, ventilators, anesthesia systems, synthetic vascular implants and stents. Extended Care's product range includes bathing and shower solutions, lifting equipment and mattresses for the treatment and prevention of pressure ulcers, as well as service and consulting. Infection Control's product range comprises disinfectors, sterilizers, information technology systems and related equipment, as well as service and consulting.
  • TickerGETI B
  • ISINSE0000202624
  • ExchangeNasdaq Nordic Stockholm
  • SectorHealth Care Equipment & Services
  • CountrySweden

Analysts

Patrik Ling

Getinge (Buy, TP: SEK145.00) - Strong growth in sales and orders

Getinge reported Q1 2019 earnings yesterday, with organic sales growth of c6% and organic order intake growth of c7.6%, better than both we and the market expected. Adjusted operating expenses rose more slowly than sales, also a positive. On the negative side, the company reported that the divestment of the mesh operation did not materialise. We keep our BUY recommendation and have raised our target price to SEK145 (SEK125) on our forecast adjustments.

Jake Strole

Getinge's First-Quarter Results Put the Firm on Track to Exceed Our Full-Year Estimates

Getinge's first-quarter results surpassed our full-year expectations on revenue and were consistent with our outlook that calls for modest margin expansion for the full year. We don't intend to make many changes to our model, but with 6% organic revenue growth, or roughly 14% as reported, management's 2%-4% organic growth target appears too conservative. Any adjustments we make will likely move our SEK 97 per share fair value estimate higher by a low- to mid-single-digit percentage for this no-m...

Håkon Astrup ...
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Stefan Gauffin

Northern Lights

Patrik Ling

Getinge (Buy, TP: SEK125.00) - Expecting a decent Q1

The Q1 results are due on 23 April at 10:30 CET. We reiterate our BUY ahead of the report and have raised our target price to SEK125 (SEK115) following an increase in our long-term forecasts. Implementation of IFRS16 should only have a marginal impact on reported EBIT, while adj. EBITA may see a slight boost, we believe. Overall focus will be on underlying sales growth and adjusted operating expenses, in our view.

Jake Strole

Morningstar | Financial Performance at Getinge Appears to be Moving in the Right Direction

Since going public in 1993, Getinge has established itself as a leading provider of surgical products and operating room supplies, patient handling equipment, and acute care devices on a global basis. Getinge’s position in these markets has been developed through acquisition, including the purchases of Arjo and Huntleigh in 1995 and 2007, respectively, Maquet in 2000, and Boston Scientific’s cardiac surgery and vascular divisions in 2008.Following the 2017 spin-off of the firm's patient and post acute care segment into the stand-alone Arjo AB entity, we anticipate more of the same from the rem...

Patrik Ling

Getinge (Buy, TP: SEK145.00) - Strong growth in sales and orders

Getinge reported Q1 2019 earnings yesterday, with organic sales growth of c6% and organic order intake growth of c7.6%, better than both we and the market expected. Adjusted operating expenses rose more slowly than sales, also a positive. On the negative side, the company reported that the divestment of the mesh operation did not materialise. We keep our BUY recommendation and have raised our target price to SEK145 (SEK125) on our forecast adjustments.

Jake Strole

Getinge's First-Quarter Results Put the Firm on Track to Exceed Our Full-Year Estimates

Getinge's first-quarter results surpassed our full-year expectations on revenue and were consistent with our outlook that calls for modest margin expansion for the full year. We don't intend to make many changes to our model, but with 6% organic revenue growth, or roughly 14% as reported, management's 2%-4% organic growth target appears too conservative. Any adjustments we make will likely move our SEK 97 per share fair value estimate higher by a low- to mid-single-digit percentage for this no-m...

Patrik Ling

Getinge (Buy, TP: SEK125.00) - Expecting a decent Q1

The Q1 results are due on 23 April at 10:30 CET. We reiterate our BUY ahead of the report and have raised our target price to SEK125 (SEK115) following an increase in our long-term forecasts. Implementation of IFRS16 should only have a marginal impact on reported EBIT, while adj. EBITA may see a slight boost, we believe. Overall focus will be on underlying sales growth and adjusted operating expenses, in our view.

Jake Strole

Morningstar | Financial Performance at Getinge Appears to be Moving in the Right Direction

Since going public in 1993, Getinge has established itself as a leading provider of surgical products and operating room supplies, patient handling equipment, and acute care devices on a global basis. Getinge’s position in these markets has been developed through acquisition, including the purchases of Arjo and Huntleigh in 1995 and 2007, respectively, Maquet in 2000, and Boston Scientific’s cardiac surgery and vascular divisions in 2008.Following the 2017 spin-off of the firm's patient and post acute care segment into the stand-alone Arjo AB entity, we anticipate more of the same from the rem...

Jake Strole

Financial Performance at Getinge Appears to be Moving in the Right Direction

No-moat Getinge reported results that we think were generally consistent with expectations, characterized by organic revenue growth in line with management's 2%-4% longer-term target and decelerating margin declines. As we roll and update our model, we don't anticipate making many changes to our longer-term projections or SEK 94 per share fair value estimate. Organic sales in the quarter were up 2.4%, growing 4.9% for the full year. Following the impressive year-to-date performance as of the fir...

1 director bought

A director at Getinge Ab bought 26,509 shares at 81.830SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Håkon Astrup ...
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Stefan Gauffin

Northern Lights

Christer Magnergård ...
  • Jesper Ingildsen
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Montgomery
  • Niclas Gehin
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Frank Maaø ...
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Marius Knudssøn ...
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Antti Kansanen ...
  • Eivind Sars Veddeng
  • Joachim Gunell
  • Jon Masdal
  • Martin Arnell
  • Martin Huseby Karlsen
  • Niclas Gehin
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

With a more favourable environment, GETINGE AB improves to Slightly Positive

GETINGE AB (SE), a company active in the Medical Equipment industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date February 5, 2019, the closing price was SEK 102.50 and its potential was estimated at SEK 107.63.

Nurhayati Wan

Getinge

null

Nurhayati Wan

Getinge

Nurhayati Wan

Getinge

null

Nurhayati Wan

Getinge

MarketLine Department

Hill-Rom Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Hill-Rom Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Hill-Rom Holdings, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive adv...

GlobalData Department

Getinge AB (GETI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Getinge AB (Getinge) is a medical technology company that designs, develops and markets equipment and instruments in the areas of surgery, infection control, intensive care, care ergonomics and wound care. Its major products include surgical tables, lights, ventilators and anesthesia equipment, heart-lung machines with accompanying disposables, equipment and instruments for cardiac surgery, vascular surgery; cardiac assist devices; patient lifting devices, hospital beds, stretchers and couches, mattresses for treating and preventing pressure sores, disinfectors, sterilization equipmen...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 04/12/2017

In general, Getinge is in compliance with the Swedish regulations relating to the organisation and procedures of an Extraordinary General Meeting.Under ITEM 7, the board of directors seeks approval to distribute all shares in the wholly-owned subsidiary Arjo to the Company's shareholders. ECGS endorses the view of the board of directors that the proposal to split the Company into two separate listed companies (Getinge and Arjo) could enhance the prerequisites to succesfully develop the respective businesses. In addition, ECGS is generally supportive towards corporate spin-offs as they give s...

Expert Corporate Governance Service (ECGS)

Etude l' AG du 15/08/2017

In general, Getinge is in compliance with the Swedish regulations relating to the organisation and procedures of an Extraordinary General Meeting. Under ITEM 7, it is proposed to add a conversion clause, providing the opportunity to convert series A shares into series B shares, to the Company's Articles of Association. As a matter of principle, we welcome the addition of such a conversion clause. The clause is intended to facilitate the spin-off of the Company's Acute Care Therapies business ("Arjo") to its shareholders. Under the Swedish Companies Act conversion is only possible on a 1:1 basi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch